Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment

被引:207
作者
Ravina, BM
Fagan, SC
Hart, RG
Hovinga, CA
Murphy, DD
Dawson, TM
Marler, JR
机构
[1] NINDS, Ctr Neurosci, NIH, Rockville, MD 20892 USA
[2] Med Coll Georgia, Dept Pharmacol, Augusta, GA 30912 USA
[3] Cleveland Clin Fdn, Dept Pharm, Cleveland, OH 44195 USA
[4] Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
D O I
10.1212/01.WNL.0000058760.13152.1A
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses. Therapies that slow the progression of PD are needed. However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials. Methods: First a broad array of compounds were identified by working with clinicians and researchers in academics and industry. Specific criteria were drafted for drug evaluation, including scientific rationale, blood-brain barrier penetration, safety and tolerability, and evidence of efficacy in animal models or humans. Agents were prioritized based on these criteria. Results: The authors identified 59 potential neuroprotective compounds, proposed by 42 clinicians and scientists from 13 countries. After systematic reviews using the specified criteria they found 12 compounds to be attractive candidates for further clinical trials in PD. Conclusions: Several potential neuroprotective compounds, representing a wide range of mechanisms, are available and merit further investigation in PD.
引用
收藏
页码:1234 / 1240
页数:7
相关论文
共 54 条
  • [1] AHLSKOG EJ, 2003, IN PRESS NEUROLOGY
  • [2] Tetracyclines for the treatment of rheumatoid arthritis
    Alarcón, GS
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (07) : 1491 - 1498
  • [3] Albin RL, 2002, JAMA-J AM MED ASSOC, V288, P311
  • [4] Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease
    Andreassen, OA
    Dedeoglu, A
    Ferrante, RJ
    Jenkins, BG
    Ferrante, KL
    Thomas, M
    Friedlich, A
    Browne, SE
    Schilling, G
    Borchelt, DR
    Hersch, SM
    Ross, CA
    Beal, MF
    [J]. NEUROBIOLOGY OF DISEASE, 2001, 8 (03) : 479 - 491
  • [5] [Anonymous], 1987, Epidemiology in Medicine
  • [6] Prospective study of caffeine consumption and risk of Parkinson's disease in men and women
    Ascherio, A
    Zhang, SMM
    Hernán, MA
    Kawachi, I
    Colditz, GA
    Speizer, FE
    Willett, WC
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (01) : 56 - 63
  • [7] Parkinson's disease and parkinsonism in a longitudinal study - Two-fold higher incidence in men
    Baldereschi, M
    Di Carlo, A
    Rocca, WA
    Vanni, P
    Maggi, S
    Perissinotto, E
    Grigoletto, F
    Amaducci, L
    Inzitari, D
    [J]. NEUROLOGY, 2000, 55 (09) : 1358 - 1363
  • [8] Oestrogen as a neuroprotective hormone
    Behl, C
    [J]. NATURE REVIEWS NEUROSCIENCE, 2002, 3 (06) : 433 - 442
  • [9] Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990
    Bower, JH
    Maraganore, DM
    McDonnell, SK
    Rocca, WA
    [J]. NEUROLOGY, 1999, 52 (06) : 1214 - 1220
  • [10] Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease
    Chen, JF
    Xu, K
    Petzer, JP
    Staal, R
    Xu, YH
    Beilstein, M
    Sonsalla, PK
    Castagnoli, K
    Castagnoli, N
    Schwarzschild, MA
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (10) : art. no. - RC143